Humacyte, Inc. (NASDAQ:HUMAW – Get Free Report)’s stock price was up 4.4% on Thursday . The company traded as high as $1.92 and last traded at $1.92. Approximately 9,470 shares were traded during mid-day trading, a decline of 69% from the average daily volume of 30,220 shares. The stock had previously closed at $1.84.
Humacyte Stock Performance
The firm’s 50 day moving average is $1.86 and its 200-day moving average is $1.83.
Humacyte Company Profile
Humacyte, Inc engages in the development and manufacture of off-the-shelf, implantable, and bioengineered human tissues for the treatment of diseases and conditions across a range of anatomic locations in multiple therapeutic areas. The company using its proprietary and scientific technology platform to engineer and manufacture human acellular vessels (HAVs) to be implanted into patient without inducing a foreign body response or leading to immune rejection.
Featured Articles
- Five stocks we like better than Humacyte
- Comparing and Trading High PE Ratio Stocks
- Microsoft Can Hit New All-Time Highs This Year – Here’s Why
- Best Aerospace Stocks Investing
- Zillow Stock’s Bull Case: Why This Recent Sell-Off Could Be a Buy
- Investing in Travel Stocks Benefits
- IonQ’s Quantum Surge: Ride the Wave or Cash Out?
Receive News & Ratings for Humacyte Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Humacyte and related companies with MarketBeat.com's FREE daily email newsletter.
